Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4217-4224

  Li, Gang ^a,b   Tian, Ling ^a   Hou, Jian Mei ^a   Ding, Zhen Yu ^a   He, Qiu Ming ^a   Feng, Ping ^a   Wen, Yan Jun ^a   Xiao, Fei ^a   Yao, Bing ^a   Zhang, Ru ^a   Peng, Feng ^a   Jiang, Yu ^a   Luo, Feng ^a   Zhao, Xia ^a   Zhang, Lin ^a   Zhou, Qiao ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING THREE GORGES UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; INTERLEUKIN 2; PHYTOHEMAGGLUTININ;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENCAPSULATION; GROWTH INHIBITION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CHEMOKINES, CXC; CISPLATIN; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20344384779     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2117     Document Type: Article

References (53)

1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
2. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
3. Marshall E. The road blocks to angiogenesis blockers. Science (Wash. DC) 1998;280:997-9.
4. Marx J. Angiogenesis: a boost for tumor starvation. Science (Wash. DC) 2003;301:452-4.
5. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumor suppressor protein ING4 regulates brain tumor growth and angiogenesis. Nature 2004;428: 328-32.
6. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52:6702-4.
7. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-7.
8. Schiller JH, Bittner G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin Cancer Res 1999; 5:4287-94.
9. Strawn LM, Kabbinavar F, Schwartz DP, et al. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res 2000;6:2931-40.
10. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
11. Morioka H, Weissbach L, Vogel T, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003;9:1211-7.
12. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270: 27348-57.
13. Luster AD, Unkeless JC, Ravetch JV. γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985;315:672-6.
14. Luster AD, Ravetch JV. Biochemical characterization of a γ interferon-inducible cytokine (IP-10). J Exp Med 1987;166:1084-97.
15. Ohmori Y, Hamilton TA. A macrophage LPS-inducible early gene encodes the murine homologue of IP-10. Biochem Biophys Res Commun 1990;168:1261-7.
16. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
17. Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001;107:53-63.
18. Luster AD, Leder P. CXCL10, a CXC chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65.
19. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-γ-inducible protein 10 (IP-10: CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168:3195-204.
20. Sgadari C, Angiolillo AL, Cherney BW, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996;93:13791-6.
21. Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon-γ-inducible protein (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastasis. J Exp Med 1996;184:981-92.
22. Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM. Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10). Cancer Immunol Immunother 2001;50:533-8.
23. Yao L, Pike SE, Pittaluga S, et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 2002;51:358-66.
24. Feldman AL, Friedl J, Lans TE, et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002;99:149-53.
25. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
26. Han ZC, Lu M, Li JM, et al. Platelet factor 4 and othe CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood 1997;89:2328-35.
27. Sarris AH, Broxmeyer HE, Wirthmueller U, et al. Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp Med 1993;178:1127-32.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
29. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993;177:1809-14.
30. Liu JY, Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003;102:1815-23.
31. Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate- encapsulated tumor cells. Cancer Res 1997;57:3847-51.
32. He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003;278:21831-6.
33. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32:2474-84.
34. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
35. Vindelov LL, Christensen IJ, Nissen NI. A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
36. Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS. Phase II trial of recombinant human interleukin-2 and interferon-α-2a: implications for the treatment of patients with metastatic melanoma. Cancer 1996;77:893-9.
37. Tulpule A, Joshi B, DeGuzman N, et al. Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma. Ann Oncol 1997;8:79-83.
38. Sparano JA, Gray R, Giantonio B, Dwyer PO, Comis RL. Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group portfolio of clinical trials. Clin Cancer Res 2004;10:1206-11.
39. Reimer CL, Agata N, Tammam JG, et al. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002;62:789-95.
40. Saris CP, van deVaart PJ, Rietbroek RC, Blommaert FA. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996;17:2763-9.
41. Faivre S, Chan D, Saunas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003;66:225-37.
42. Zhong X, Li X, Wang G, et al. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol 2004;25:445-51.
43. Yang JM, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004;9:846-55.
44. Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60: 2169-77
45. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6.
46. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804-14.
47. Schmidt NO, Ziu M, Carrabba G, et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 2004;10:1255-62.
48. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003;13:159-67.
49. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:15-24.
50. Williams J, Weitman S, Gonzalez CM, et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 2001;7:724-33.
51. Tunggal JK, Cowan DSM, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 1999;5:1583-6.
52. Curnis F, Sacchi A, Corti A, Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110: 475-82.
53. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor α (NGR-TNF) and doxorubicin. Cancer Res 2004;64:7150-5.